{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = [(8''R'',9''S'',13''S'',14''S'',17''S'')-17-[2-[4-[4-[''bis''(2-Chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate
| image = Atrimustine.svg
| width = 250

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 75219-46-4
| CAS_supplemental = 
| ATC_prefix = 
| ATC_suffix = 
| PubChem = 6917688
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 5292918
| UNII = XC0K09B7K4
| ChEMBL = 2106381

<!--Chemical data-->
| C=41 | H=47 | Cl=2 | N=1 | O=6
| molecular_weight = 
| smiles = C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)c5ccccc5)ccc34)[C@@H]1CC[C@@H]2OC(=O)COC(=O)CCCc6ccc(cc6)N(CCCl)CCCl
| StdInChI_Ref = 
| StdInChI = 1S/C41H47Cl2NO6/c1-41-21-20-34-33-17-15-32(49-40(47)29-7-3-2-4-8-29)26-30(33)12-16-35(34)36(41)18-19-37(41)50-39(46)27-48-38(45)9-5-6-28-10-13-31(14-11-28)44(24-22-42)25-23-43/h2-4,7-8,10-11,13-15,17,26,34-37H,5-6,9,12,16,18-25,27H2,1H3/t34-,35-,36+,37+,41+/m1/s1
| StdInChIKey_Ref = 
| StdInChIKey = IFJUINDAXYAPTO-UUBSBJJBSA-N
| synonyms = Estradiol 3-benzoate 17β-((4-(4-(bis(2-chloroethyl)amino)phenyl)-1-oxobutoxy)acetate; 3-Benzoyl-17β-((4-(4-(bis(2-chloroethyl)amino)phenyl)-1-oxobutoxy)acetylestradiol<ref name="Elks2014" />
}}

'''Atrimustine''' ([[International Nonproprietary Name|INN]]) (developmental code name '''KM-2210'''), also known as '''bestrabucil''' or '''busramustine''', is a [[nitrogen mustard]] [[alkylating antineoplastic agent|alkylating]] [[antineoplastic drug]] that was under development in [[Japan]] by [[Kureha Chemical Industries|Kureha Chemicals]] (now Kureha Corporation) for the treatment of [[breast cancer]] and [[non-Hodgkin's lymphoma]] as well as for the prevention of [[graft-versus-host disease]] in [[bone marrow transplant]] recipients.<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PR2|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=897–898}}</ref><ref name="Publishing2013">{{cite book|author=William Andrew Publishing|title=Pharmaceutical Manufacturing Encyclopedia, 3rd Edition|url=https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA438|date=22 October 2013|publisher=Elsevier|isbn=978-0-8155-1856-3|pages=438–}}</ref>[http://webcache.googleusercontent.com/search?q=cache:aYPjqAoRa84J:adisinsight.springer.com/drugs/800000756+&cd=9&hl=en&ct=clnk&gl=us] It is the [[benzoate]] [[ester]] of an [[ester]] [[conjugated system|conjugate]] of [[estradiol]] and [[chlorambucil]],<ref>{{cite book|title=The Cancer Bulletin|url=https://books.google.com/books?id=mZMVAQAAMAAJ|year=1987|publisher=Medical Arts Publishing Foundation|page=245}}</ref> which results in targeted/site-directed DNA alkylating activity toward [[estrogen receptor]]-positive tissues such as [[breast]] and [[bone]].<ref name="pmid6548354">{{cite journal | vauthors = Ohsawa N, Yamazaki Z, Wagatsuma T, Isurugi K | title = [Bestrabacil: a possible target-oriented anticancer agent] | language = Japanese | journal = Gan to Kagaku Ryoho | volume = 11 | issue = 10 | pages = 2115–24 | year = 1984 | pmid = 6548354 | doi = | url = }}</ref><ref name="Ishigami1985">{{cite book|author=Joji Ishigami|title=Recent Advances in Chemotherapy: Proceedings of the 14th Internat. Congress of Chemotherapy, Kyoto, 1985. Antimicrobial section ; 1. 1 ,1|url=https://books.google.com/books?id=AKQTAQAAMAAJ|year=1985|publisher=University of Tokyo Press|isbn=978-0-86008-385-6|page=52,54,471}}</ref> It reached [[marketing authorization|preregistration]] for the treatment of [[cancer]] but was ultimately discontinued.[http://webcache.googleusercontent.com/search?q=cache:aYPjqAoRa84J:adisinsight.springer.com/drugs/800000756+&cd=9&hl=en&ct=clnk&gl=us]{{dead link|date=October 2016 |bot=InternetArchiveBot |fix-attempted=yes }} [[Estrogen]]ic [[side effect]]s of atrimustine in [[clinical trial]]s included [[vaginal bleeding]] and [[gynecomastia]].[http://webcache.googleusercontent.com/search?q=cache:aYPjqAoRa84J:adisinsight.springer.com/drugs/800000756+&cd=9&hl=en&ct=clnk&gl=us] The drug was first patented in 1980.<ref name="Elks2014" />

==See also==
* [[Alestramustine]]
* [[Cytestrol acetate]]
* [[Estradiol mustard]]
* [[Estramustine phosphate]]
* [[ICI-85966]]
* [[Prednimustine]]
* [[Sturamustine]]
* [[Uramustine]]

==References==
{{Reflist}}

{{Estrogen receptor modulators}}

[[Category:Estradiol esters]]
[[Category:Estranes]]
[[Category:Estrogens]]
[[Category:Nitrogen mustards]]
[[Category:Abandoned drugs]]

{{antineoplastic-drug-stub}}
{{genito-urinary-drug-stub}}
{{steroid-stub}}